Helicobacter pylori prevalence fueling demand in the Gastric Cancer Therapy Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Gastric Cancer Therapy Market Projected To Become By 2030 Based On Its 2026 Valuation?

The market for gastric cancer treatment has experienced robust expansion over recent years. This market is projected to expand from $4.5 billion in 2025 to reach $4.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.3%. Factors contributing to its historical growth include the restricted availability of targeted therapies, a reliance on traditional chemotherapy and surgical interventions, the rising incidence of gastric cancer, an expansion in hospital oncology infrastructure, and greater awareness regarding early detection initiatives.

The gastric cancer therapy market is anticipated to experience substantial expansion in the coming years. Its valuation is projected to reach $6.96 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.1%. This anticipated growth during the forecast period stems from factors such as the emergence of innovative immunotherapies and checkpoint inhibitors, the increasing acceptance of precision medicine, the proliferation of outpatient oncology services, augmented financial commitment to gastric cancer research, and the incorporation of digital health instruments for patient oversight. Key developments expected during this period involve a greater embrace of targeted and personalized treatment methods, an uptick in the application of combination therapy strategies, an expansion of initiatives for early detection and screening, the broadening availability of home care and mobile treatment alternatives, and a heightened emphasis on mitigating side effects and enhancing patients’ overall quality of life.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25767&type=smp

Which Market Drivers Are Supporting The Expansion Of The Gastric Cancer Therapy Market?

An increasing prevalence of Helicobacter pylori infection is projected to propel the growth of the gastric cancer therapy market in the coming years. This bacterial condition primarily impacts the stomach lining and is a significant contributor to chronic gastritis and gastric cancer. The growing incidence of Helicobacter pylori infection largely stems from inadequate sanitation, given that poor hygiene and tainted food or water facilitate its oral-oral or fecal-oral transmission. Gastric cancer therapy aids in mitigating the risk of stomach cancer linked to Helicobacter pylori by addressing the infection, reducing related gastric inflammation and cellular harm, and halting the advancement of chronic gastritis and atrophic alterations that can lead to malignant changes in the gastric mucosa. For instance, a report from November 2024 by the Government of Canada, a Canada-based administration, indicated that as of January 2023, the recurrence rate for H. pylori infection was projected to reach up to 19%, though it shows variation depending on geography and age. Consequently, the increasing occurrence of Helicobacter pylori infection is serving as a primary impetus for the expansion of the gastric cancer therapy market.

What Segment Groups Are Identified Within The Gastric Cancer Therapy Market?

The gastric cancer therapy market covered in this report is segmented –

1) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery

2) By Drug Class: Cytotoxic Agents, Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Checkpoint Inhibitors, Miscellaneous Agents

3) By Administration Route: Oral, Intravenous, Intramuscular, Subcutaneous

4) By Stage of Disease: Early Stage, Locally Advanced Stage, Metastatic Stage

5) By End User: Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Research Institutions, Home Care Settings

Subsegments:

1) By Chemotherapy: Neoadjuvant Chemotherapy (NAC), Adjuvant Chemotherapy (AC), Palliative Chemotherapy (PC), Combination Chemotherapy, Monotherapy

2) By Targeted Therapy: Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Therapy, Vascular Endothelial Growth Factor (VEGF) Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Mesenchymal-Epithelial Transition (MET) Inhibitors, Claudin 18 Isoform 2 Inhibitors

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Transfer, Cytokine Therapy, Combination Immunotherapy

4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Three-Dimensional Conformal Radiation Therapy (3D-CRT), Brachytherapy

5) By Surgery: Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Subtotal Gastrectomy, Total Gastrectomy, Lymphadenectomy

What Trends Are Advancing Progress In The Gastric Cancer Therapy Market?

Leading companies in the gastric cancer therapy market are prioritizing the development of innovative treatments, such as combination therapy, to enhance treatment efficacy and patient outcomes. Combination therapy entails the simultaneous use of two or more treatments, including chemotherapy, targeted therapy, or immunotherapy, to boost overall effectiveness. For example, in December 2024, BeOne Medicines Ltd., a China-based pharmaceutical company previously known as BeiGene, gained approval from the U.S. Food and Drug Administration (FDA) for Tevimbra (tislelizumab-jsgr) in conjunction with platinum- and fluoropyrimidine-based chemotherapy. This approval is for the first-line treatment of adults afflicted with unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma whose tumors express PD-L1 (=1). The basis for this approval came from data from the Phase 3 RATIONALE-305 trial, which demonstrated that this combination therapy significantly improved median overall survival to 15.0 months, compared to 12.9 months with chemotherapy alone, representing a 20% reduction in the risk of death. This milestone emphasizes a rising trend among key pharmaceutical firms to invest in novel, multimodal treatment strategies that integrate immunotherapy with conventional chemotherapy regimens to improve clinical results, delay disease progression, and elevate survival rates in patients suffering from advanced gastric cancer.

Which Companies Hold Significant Positions In The Gastric Cancer Therapy Market?

Major companies operating in the gastric cancer therapy market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Hutchison MediPharma Limited, Shanghai Henlius Biotech Inc.

Read the full gastric cancer therapy market report here:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-therapy-global-market-report

How Is The Gastric Cancer Therapy Market Distributed Across Key Geographic Regions?

North America was the largest region in the gastric cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Gastric Cancer Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25767&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Therapy Market 2026, By The Business Research Company

Gastric Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Cancer Diagnostic Procedure Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-diagnostic-procedure-global-market-report

Intestine Cancer Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795